* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project
Download Reading Material
Discovery and development of beta-blockers wikipedia , lookup
Drug design wikipedia , lookup
Neuropharmacology wikipedia , lookup
Discovery and development of proton pump inhibitors wikipedia , lookup
Pharmacognosy wikipedia , lookup
Plateau principle wikipedia , lookup
Pharmaceutical industry wikipedia , lookup
Prescription drug prices in the United States wikipedia , lookup
Drug discovery wikipedia , lookup
Prescription costs wikipedia , lookup
Neuropsychopharmacology wikipedia , lookup
Pharmacogenomics wikipedia , lookup
Drug interaction wikipedia , lookup
GENDER DIFFERENCES IN CLINICAL RESEARCH GAUTAM CHAUDHURI, M.D., Ph.D. CARLA JANZEN, M.D. LAUREN NATHAN, M.D. BARBARA A. LEVEY, M.D. DEPARTMENTS OF OBSTETRICS AND GYNECOLOGY AND MOLECULAR AND MEDICAL PHARMACOLOGY DAVID GEFFEN SCHOOL OF MEDICINE AT UCLA 1 DEFINITIONS • SEX refers to the classification of living things, generally as male or female, according to their reproductive organs and functions assigned by chromosomal complement. • GENDER refers to a person’s selfrepresentation as male or female. Gender is rooted in biology and shaped by environment and experience. 2 SEX DIFFERENCES IN RECOVERY FROM STROKE • Females are more likely than males to recover language ability after suffering a left hemisphere stroke • Men and women differ in brain organization for language – Men rely on left inferior frontal gyrus to carry out language tasks – Women use both the right and left inferior gyri to carry out certain language tasks 3 SEX DIFFERENCES AND DEPRESSION • Female gender is a major risk of depression by 2:1 ratio • Prevalence of major depression in women (21.3%) versus men (12.7%) 4 WOMEN IN CLINICAL TRIALS • FDA 1977 guidelines directed that women of childbearing potential be excluded from Phase I and early Phase II trials but women could participate later. • Child bearing potential was narrowly defined as any woman physiologically capable of becoming pregnant, regardless of sexual activity, sexual practices and contraceptive use • In 1990, the NIH directed that women and minorities be included in clinical trials 5 SEX DIFFERENCES • Physiological factors • Molecular factors 6 SEX DIFFERENCES AND CLINICAL RESEARCH • The following should be considered – Genetic differences – Phase of menstrual cycle – Premenopausal vs. postmenopausal – Use of oral contraceptives or hormone replacement therapy – Pregnancy – Lactation 7 SEX DIFFERENCES • Physiological factors – Generally lower • Body weight • Organ size • Glomerular filtration rate – Generally higher • Percentage of body fat – Different gastric motility in women compared to men 8 GENETIC/MOLECULAR BASIS OF SEX BASED DIFFERENCES • Genetic/molecular basis of sex-based differences may be due to: – Sexual genotype – Genes on sex chromosomes may be expressed differently between males and females (single or double copies of the gene, differing meiotic effects, X chromosome inactivation, genetic imprinting) – Source of X chromosome (maternal or paternal) 9 MOLECULAR FACTORS • Men seem to have higher activity relative to women for: – Cytochrome P 450 (cyp) isoenzymes • Cyp 1A2 • Cyp 2E1 – Drug efflux transporter • P-glycoprotein • Some isoforms of glucuronyl transferase and sulfotransferases • Women have higher – Cyp 2D6 activity – Cyp 3A4 activity 10 PRINCIPLES OF DRUG ACTION • • • • • • Absorption Bioavailability Volume of distribution Plasma protein binding Action on receptor site Termination of activity – Redistribution – Metabolism – Renal excretion 11 SEX DIFFERENCES AND ANTIDEPRESSANT PHARMACOKINETICS • Oral contraceptives decrease the hepatic metabolism of imipramine because of changes in hepatic blood flow • Imipramine dosage reduction is necessary in chronic long-term oral contraceptive users to 2/3rd that given to non-contraceptive users • Women older than 50 years have higher plasma concentrations of amitriptyline than age matched men 12 BIOAVAILABILITY OF DRUGS • Extent to which and the rate at which an administered drug dose reaches the systemic circulation unchanged • Bioavailability of a drug administered intravenously is equal to unity • Bioavailability of a compound administered as an oral, intramuscular, or subcutaneous formulation is assessed in relation to intravenous drug 13 HALF-LIFE OF A DRUG volume of distribution Half-life = clearance 14 X log c2 DISTRIBUTION OF DRUGS • Rate at which equilibrium between tissue and plasma concentration is achieved depends on: – Blood perfusion rate to organs – Drug lipid solubility – Drug’s ability to bind to proteins or tissues 15 LIPID SOLUBILITY AND DISTRIBUTION OF DRUGS • If lipid soluble – more likely to cross biological barriers such as cell membranes, blood-brain barrier, and placenta • If water soluble – will cross membranes only if it’s of small molecular size 16 DRUG METABOLISM • Water soluble drugs – Eliminated unchanged after glomerular filtration • Lipid-soluble drugs – Rendered more polar by metabolism prior to excretion in bile or urine – Oxidation (hydroxylation, demethylation) – Conjugation (glucoronide, sulphate) 17 PHYSIOLOGICAL CHANGES IN PREGNANCY • • • • • • Total body water increases - up to 8 liters Plasma volume increases by 50% Plasma albumin falls by 5-10 g/L Increase in body fat by 3-4 kg Increase in body weight Maternal cardiac output increases by 30-50% during pregnancy (4.5 l/min 6 l/min) 18 EFFECTS OF INCREASE IN CARDIAC OUTPUT •Uterine circulation 500 ml/min at term •Effective renal plasma flow Increased by 75% over nonpregnant levels to 891 ml/min by 26 weeks (NP – 480 ml/min) •Glomerular filtration rate Increased by 50% from 99 ml/min – non-pregnant to 152 ml/min – by 26 weeks •Creatinine clearance rate 150-200 ml/min 19 INFLUENCE OF PHYSIOLOGICAL CHANGES IN PREGNANCY ON DRUG HANDLING • Ingestion – Compliance • Fear that fetus may be harmed • Nausea, vomiting and heartburn • Absorption – Gastric function • Delayed gastric emptying • Gastric acid secretion is decreased by 40% – Functions of small intestine – GI transit is prolonged by 30-50% – Drugs if metabolized in gut wall eS chlorpromazine, may reduce bioavailability • Epidural space – Greatly increased vascularity in epidural space • Demerol more rapidly absorbed 20 CYTOCHROME P-450 AND SEX STEROIDS • High levels of progesterone may inhibit some enzymes of P-450 system – CYP 1A2 leading to decreased elimination of theophylline, caffeine, and zileuton • High levels of progesterone may increase activity of some enzymes – CYP 3A4 and CYP 2C9 leading to increase in hepatic elimination of drugs like phenytoin and sertraline 21 ANTICONVULSANTS AND PREGNANCY • Phenytoin – Increased clearance resulting in lower serum concentrations – absorption • plasma protein binding • metabolism 22 DRUG METABOLISM IN PREGNANCY PHENYTOIN CARBAMAZEPINE OXIDATION PHENOLIC COMPOUNDS OXIDATION ARENE OXIDES (EPOXIDES) PHENOLIC COMPOUNDS ARENE OXIDES (EPOXIDES) HYDROLYZED HYDROLYZED CONJUGATION WITH GLUCURONIC ACID CONJUGATION WITH GLUCURONIC ACID 23 ANTIBIOTIC LEVELS AFFECTED DURING PREGNANCY • Ampicillin, penicillin, cefazolin levels decreased by 50% • Gentamycin, tobramycin, and amikacin serum concentrations are also reduced 24 ASTHMA THERAPY AND PREGNANCY – Inhaled steroids and beta agonists commonly used – Theophylline serum concentrations can be elevated during pregnancy ( CYP 1A2) 25 CARDIOVASCULAR AGENTS AND PREGNANCY • Serum concentrations of propranolol, labetalol, and atenolol not changed • Lowered serum concentrations with metoprolol 26 SUBSTRATES - 1 1A2 2B6 2C19 2C9 2D6 2E1 3A4, 5, 7 amitriptyline caffeine clomipramine clozapine cyclobenzaprine (Flexeril®) estradiol fluvoxamine haloperidol imipramine NDeMe mexiletine naproxen ondansetron phenacetin=> acetaminophen =>NAPQI propranolol riluzole ropivacaine tacrine theophylline verapamil (R)warfarin zileuton zolmitriptan bupropion cyclophosphamide ifosfamide Proton Pump Inhibitors: lansoprazole omeprazole pantoprazole E-3810 Anti-epileptics: diazepam=>Nor phenytoin(O) S-mephenytoin phenobarbitone amitriptyline citalopram clomipramine cyclophosphamide hexobarbital imipramine N-DeME indomethacin R-mephobarbital moclobemide NSAIDs: diclofenac ibuprofen meloxicam S-naproxen=>Nor piroxicam suprofen Oral Hypoglycemic Agents: tolbutamide glipizide Angiotensin II Blockers: losartan irbesartan amitriptyline celecoxib fluoxetine fluvastatin glyburide phenytoin=>4-OH Beta Blockers: carvedilol S-metoprolol propafenone timolol Antidepressants: amitriptyline clomipramine desipramine imipramine paroxetine Antipsychotics: haloperidol perphenazine risperidone=>9OH thioridazine alprenolol amphetamine bufuralol chlorpheniramine chlorpromazine Anesthetics: enflurane halothane isoflurane methoxyflurane sevoflurane acetaminophen =>NAPQI aniline benzene chlorzoxazone ethanol N,N-dimethyl formamide theophylline =>8-OH Macrolide antibiotics: clarithromycin erythromycin (not 3A5) NOT azithromycin Anti-arrhythmics: quinidine=>3-OH (not 3A5) Benzodiazepines: alprazolam diazepam=>3OH midazolam triazolam Immune Modulators: cyclosporine tacrolimus (FK506) 27 SUBSTRATES - 2 1A2 2B6 2C19 2C9 2D6 nelfinavir nilutamide primidone progesterone proguanil propranolol teniposide R-warfarin=>8OH rosiglitazone tamoxifen torsemide S-warfarin codeine (=>OdesMe) debrisoquine dexfenfluramine dextromethorphan encainide flecainide fluoxetine fluvoxamine lidocaine metoclopramide methoxyamphetamine mexiletine nortriptyline minaprine ondansetron perhexiline phenacetin phenformin propranolol (=>4OH) quanoxan sparteine tamoxifen tramadol venlafaxine 28 2E1 3A4, 5, 7 HIV Antivirals: indinavir nelfinavir ritonavir saquinavir Prokinetic: cisapride Antihistamines: astemizole chlorpheniramine terfenidine Calcium Channel Blockers: amlodipine diltiazem felodipine lercanidipine nifedipine nisoldipine nitrendipine verapamil SUBSTRATES - 3 1A2 2B6 2C19 2C9 2D6 2E1 3A4, 5, 7 HMG CoA Reductase Inhibitors: atorvastatin cerivastatin lovastatin NOT pravastatin simvastatin Steroid 6beta-OH: estradiol hydrocortisone progesterone testosterone Miscellaneous: alfentanyl buspirone caffeine=>TMU cocaine dapsone=>N-OH codeine- Ndemethylation dextromethorphan fentanyl finasteride haloperidol irinotecan LAAM lidocaine 29 SUBSTRATES - 4 1A2 2B6 2C19 2C9 2D6 2E1 3A4, 5, 7 methadone odanestron pimozide propranolol quinine salmeterol sildenafil sirolimus tamoxifen taxol terfenadine trazodone vincristine zaleplon zolpidem 30 RECOMMENDATIONS • Clarify use of terms sex and gender • Determine and disclose the sex of origin of biological research materials • Identify endocrine status of research subjects • Design studies so that results can be analyzed by sex • Promote research on sex at the cellular level • Encourage and support interdisciplinary research on sex differences 31